Скачать или смотреть Prostate Cancer Breakthrough: Drug Halves Death Risk Now Available on NHS

Prostate cancer treatment darolutamide Nubeqa NHS
Discover the latest in prostate cancer treatment as NICE approves darolutamide (Nubeqa) for thousands of men in England. This new drug, combined with androgen deprivation therapy, can halve the risk of death from metastatic hormone-sensitive prostate cancer.
Learn how darolutamide works by blocking hormones that fuel cancer growth, offering fewer side effects than existing treatments. We'll cover the NICE guidance, Bayer's role, and quotes from experts on accessibility and the postcode lottery in cancer care.
Find out why Prostate Cancer UK calls it a 'gentler' option, and how it compares to other therapies already on the NHS. This video explores the clinical trials showing a 46% reduction in death risk, and the push for better cancer care in the national cancer plan.
Stay informed on advancements in prostate cancer research and treatments.